HYPERTRIGLYCERIDEMIA DURING TREATMENT WITH ADALIMUMAB IN PSORIATIC ARTHRITIS

A 39-year-old man with a 1-year history of psoriatic arthritis was treated with adalimumab 40 mg every 2 weeks subcutaneously. After 8 weeks of treatment the patient developed hypercholesterolaemia (267 mg/dL), hypertriglyceridaemia (449 mg/)and weakness; we decided to continue treatment and after 3 months of therapy the patient developed a severe weakness and a remarkable hypertriglyceridaemia (689 mg/dL) while total serum cholesterol levels remained unchanged (264 mg/dL). Because of these important alterations we decided to discontinue therapy with the biological drug and after 4 weeks the TG level was 220 mg/dL), cholesterol level was 224 mg/dL) and weakness was notably improved.